Start Date
End Date
IMI2 - Call 11
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
1 750 000
EFPIA in kind
1 350 688
Total Cost
3 100 688


IMI’s GETREAL project delivered a range of new tools and resources for incorporating real-life data earlier into drug development and decision making processes. The aim of the GETREAL Initiative is to drive the adoption of these tools and so increase the quality of real-world evidence (RWE) generation in medicines development and regulatory /health technology assessment processes. Specifically, the project will set up a think tank comprising international thought leaders to discuss, assess and give recommendations on opportunities and barriers to the generation, use and acceptability of RWE. The members will also act as ambassadors for the use of RWE, engaging with key stakeholder groups to facilitate the uptake of the project outputs. The project will also set up a number of task forces to drive the development of specific GETREAL outputs in the areas of pragmatic trials; network meta-analysis and benefit-risk assessment; and statistical approaches for enriching clinical trials with real world data. Finally, the project will create a RWE research community including researchers with expertise in RWE generation as well as regulators, health technology assessment (HTA) bodies, physicians and patients. The community will provide feedback on guidelines, recommendations and white papers produced by the project.

Achievements & News

Participants Show participants on map

EFPIA companies
  • Amgen Limited, Cambridge, United Kingdom
  • Astellas Pharma Europe BV, Leiden, Netherlands
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
  • UCB Biopharma SRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • National Institute For Health And Care Excellence, Manchester, United Kingdom
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • L.A Sante, Epidemiologie, Evaluation Et Recherche L.A.S.E.R., Paris, France
  • Vital Transformation, Wezembeek Oppem, Belgium
  • Zorginstituut Nederland, Diemen, Netherlands
Patient organisations
  • International Alliance Of Patient'Organizations, London, United Kingdom
Project coordinator
Diederick Grobbee
Universitair Medisch Centrum Utrecht
Project leader
Elaine Irving
Glaxosmithkline Research And Development LTD